Claims for Patent: 7,951,781

Summary for Patent: 7,951,781

Title:	Methods and compositions related to PLUNC surfactant polypeptides
Abstract:	Embodiments include compositions and methods for lower the surface tension of a liquid-air interface by contacting such interface with all or part of a PLUNC polypeptide.
Inventor(s):	McCray, Jr.; Paul B. (Iowa City, IA), Gakhar; Lokesh (Iowa City, IA), Mallampalli; Rama K. (Iowa City, IA), Ramaswamy; Subramanian (Iowa City, IA), Bartlett; Jennifer (Coralville, IA)
Assignee:	University of Iowa Research Foundation (Iowa City, IA)
Application Number:	11/934,581
Patent Claims:	1. A therapeutic method of lowering surface tension at a liquid-air interface comprising administering to a subject in need thereof an amount of an isolated palate, lung and nasal epithelial clone (PLUNC) polypeptide sufficient to lower the surface tension at the liquid-air interface, wherein said subject suffers from cystic fibrosis or chronic obstructive pulmonary disorder, and wherein the PLUNC polypeptide comprises at least 10 consecutive residues from amino acids 21 to 256 of SEQ ID NO:2. 2. The method of claim 1, wherein the PLUNC polypeptide comprises an amino acid sequence of 10 to 200 consecutive amino acids of amino acids 21 to 256 of SEQ ID NO:2. 3. The method of claim 1, wherein PLUNC polypeptide is administered at a dose of 1 .mu.g to 100 mg per kg of body weight. 4. The method of claim 1, wherein the liquid-air interface is part of the respiratory system or auditory system of a subject. 5. The method of claim 4, wherein the liquid-air interface is present in a subject's upper respiratory system, trachea, mouth, or lungs. 6. The method of claim 4, wherein the liquid-air interface is present in a subject's Eustachian tubes. 7. The method of claim 4, wherein administration is by endotracheal administration. 8. The method of claim 4, wherein administration is by inhalation. 9. The method of claim 4, further comprising a second therapy. 10. The method of claim 9, wherein the second therapy is a respiratory therapy. 11. The method of claim 10, wherein the respiratory therapy is conventional ventilation, high frequency ventilation, or continuous positive airway pressure. 12. The method of claim 9, wherein the second therapy is administration of one or more therapeutic agents. 13. The method of claim 12, wherein the other therapeutic agents are nitric oxide, steroids, antioxidants, vitamins, vitamin derivatives, reactive oxygen scavengers, bronchodilators, diuretics, antimicrobial agents, anti-infective agents, anti-hypertensive agents or anti-inflammatory agents. 14. The method of claim 1, further comprising administering a pulmonary surfactant. 15. The method of claim 14, wherein the pulmonary surfactant is Poractant Alfa, Beractant, Bovactant, Colfosceril Palmitate, Surfactant-Ta, Calfactant, Pumactant, Lusupultide or Sinapultide. 16. The method of claim 1, further comprising administering an antibiotic to said subject. 17. The method of claim 16, wherein the antibiotic therapy comprises administration of penicillin, ampicillin, amoxycillin, vancomycin, cycloserine, bacitracin, cephalolsporin, imipenem, colistin, methicillin, streptomycin, kanamycin, tobramycin, gentamicin, tetracycline, chlortetracycline, doxycycline, chloramphenicol, lincomycin, clindamycin, erythromycin, oleandomycin, polymyxin nalidixic acid, rifamycin, rifampicin, gantrisin, trimethoprim, isoniazid, paraaminosalicylic acid, or ethambutol. 18. A method of enhancing effectiveness of anti-microbial agents comprising administering to a subject in need thereof a palate, lung and nasal epithelial clone (PLUNC) polypeptide comprising at least 10 consecutive residues of amino acids 21 to 256 of SEQ ID NO:2 and an anti-microbial, wherein the PLUNC polypeptide lowers the surface tension of a liquid-air interface and enhances dispersion of the anti-microbial, wherein said subject suffers from cystic fibrosis or chronic obstructive pulmonary disorder. 19. The method of claim 18, wherein the PLUNC polypeptide is an amino terminal fragment of a PLUNC polypeptide comprises an amino acid sequence of 10 to 200 amino acids of the amino terminal sequence of SEQ ID NO:2. 20. A method of enhancing effectiveness of a surfactant comprising administering to a subject in need thereof a palate, lung and nasal epithelial clone (PLUNC) polypeptide comprising at least 10 consecutive residues of amino acids 21 to 256 of SEQ ID NO:2 and a surfactant, wherein the PLUNC polypeptide lowers the surface tension of a liquid-air interface produced by the surfactant alone, and wherein said subject suffers from cystic fibrosis or chronic obstructive pulmonary disorder. 21. The method of claim 1, wherein the PLUNC polypeptide comprises amino acids 21 to 256 of SEQ ID NO:2. 22. The method of claim 18, wherein the PLUNC polypeptide comprises amino acids 21 to 256 of SEQ ID NO:2. 23. The method of claim 20, wherein the PLUNC polypeptide is an amino terminal fragment of a PLUNC polypeptide comprises an amino acid sequence of 10 to 200 amino acids of the amino terminal sequence of SEQ ID NO:2. 24. The method of claim 20, wherein the PLUNC polypeptide comprises amino acids sequence 21 to 256 of SEQ ID NO:2.

Details for Patent 7,951,781

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	July 01, 1991		2026-11-02
Ony Biotech Inc.	INFASURF	calfactant	Suspension	020521	July 01, 1998		2026-11-02
Ony Biotech Inc.	INFASURF	calfactant	Suspension	020521	December 12, 2002		2026-11-02
Ony Biotech Inc.	INFASURF	calfactant	Suspension	020521			2026-11-02
Chiesi Usa, Inc.	CUROSURF	poractant alfa	Suspension	020744	November 18, 1999		2026-11-02